T3D Therapeutics, Inc., a clinical stage drug development company engaged in the development of a new orally administered treatment for Alzheimer’s disease (AD), today announced that preliminary Phase 2a data with T3D-959 in mild to moderate Alzheimer’s disease subjects were reviewed in a poster presentation at the 2016 Alzheimer’s Association International Conference (AAIC).